What is the market's earnings forecast for Novavax next quarter?

What is Novavax's latest dividend and current dividend yield?

What factors drove the changes in Novavax's revenue and profit?

What were the key takeaways from Novavax’s earnings call?

What were the key takeaways from Novavax's earnings call?

What does Novavax do and what are its main business segments?

What guidance did Novavax's management provide for the next earnings period?

What is the revenue and EPS growth rate for Novavax year over year?

- **Revenue milestone**: $1.1B in 2025, up 65% YoY, with $800M+ in non-dilutive capital from partnerships.
- **Matrix-M expansion**: 2 new disease areas with Pfizer, oncology MTA signed, and $200M+ per-partner royalty potential.
- **Pipeline progress**: C. diff vaccine IND targeting 2027, shingles/RSV combo candidates in preclinical stages.
- **Cost efficiency**: 42% YoY expense reduction, $200M 2028 run rate target, and $857M cash at year-end.
- **Sanofi combo vaccine**: $125M Phase III milestone at risk, with 2026 flu/COVID launch expected.

**【CEO Summary Section】**
- Highlighted 2025 progress: $800M+ in non-dilutive capital from partnerships, 65% YoY revenue growth, and $857M in cash at year-end.
- Strategic focus on Matrix-M adjuvant platform: 2 new disease areas with Pfizer, expanded MTA with major pharma, and oncology partnership signed in Q1 2026.
- R&D pipeline: C. diff vaccine candidate shows promise in preclinical studies, targeting IND in 2027; shingles and RSV combo vaccines in early stages.
- Cost reduction: 42% YoY decline in non-GAAP R&D/SG&A, targeting $200M annual run rate by 2028.

**【CFO Financial Commentary】**
- 2025 total revenue: $1.1B (65% YoY growth), driven by $625M non-cash APA resolutions and $22M Sanofi royalties.
- Operating efficiency: $500M GAAP expenses vs. $42M non-GAAP favorability, with $80M+ new capital from Pfizer and credit facility.
- Cash runway: $857M at year-end + Q1 2026 inflows, funding operations into 2028 without new equity.
- 2026 revenue framework: $230-270M adjusted licensing/royalties, including $30M Pfizer upfront and $70M+ Sanofi R&D reimbursements.

**【Q&A Highlights】**
- **Sanofi partnership update**: 2026 flu/COVID combo Phase III initiation expected, with $125M milestone potential.
- **C. diff vaccine progress**: Multivalent antigen approach targeting 95%+ of circulating strains, showing superior efficacy vs. toxin-only candidates.
- **Matrix-M expansion**: New dry powder formulation for oncology applications, with $200M+ potential per partner in future vaccines.
- **Regulatory environment**: Optimistic about 2026 ACIP meeting, with Nuvaxovid safety/tolerability profile differentiated from mRNA vaccines.
- **Partnership pipeline**: 10+ active MTAs, including oncology and pharma expansions, with $500M+ potential in new deals this year.

Novavax, Inc.(NVAX)-20260226-2025 Q4 Earnings call transcript

- **Strategic Transformation**: Novavax transitions to a diversified pipeline, reducing costs and pursuing partnerships for 2028 non-GAAP profitability.
- **Financial Performance**: Q3 2025 revenue $70M, driven by Sanofi milestones. 2026 R&D/SG&A target $450M (net of reimbursements).
- **Pipeline Progress**: BARDA grant for Sanofi's pandemic flu vaccine; CIC Phase III potential in 2026. Shingles vaccine shows superior tolerability.
- **Risk Factors**: Dependency on partner execution for profitability; regulatory delays in CIC program.

**【CEO Summary Section】**
- Novavax has transformed into a lean, agile organization, transitioning from a single-product focus to a diversified pipeline. Key achievements include a $1 billion reduction in liabilities and $1.1 billion in nondilutive cash flow through partnerships.
- Strategic priorities: optimizing partnerships (e.g., Sanofi, Takeda), advancing R&D (C. diff, shingles, RSV), and reducing costs. 2028 non-GAAP profitability target contingent on partner execution.
- Q3 2025 highlights: $70 million revenue, $225 million in Sanofi milestones, and $25 million from Takeda. R&D pipeline includes Matrix-M in oncology and C. diff vaccines.

**【CFO Financial Commentary】**
- Q3 2025: $70 million revenue (down 18% YoY), $130 million R&D/SG&A expenses (down 18% YoY). Royalties and R&D reimbursements drive $57 million in licensing revenue.
- 2026 guidance: $520 million R&D/SG&A (net of partner reimbursements), narrowing to $450 million midpoint. 2027 target: $250 million net spend. $126 million noncash charges in Q3 for site consolidation and debt refinancing.
- BARDA grant for Sanofi's pandemic flu vaccine with Matrix-M; potential Phase III for CIC in 2026.

**【Q&A Highlights】**
- **Sanofi Collaboration**: Positive Phase I/II data for COVID-flu combo; 2026 Phase III possible. Novavax eligible for royalties and milestones. 2025 COVID sales $23M, 2026 expected to grow as Sanofi leads U.S. commercialization.
- **Matrix-M in Oncology**: Early-stage exploration shows promise; potential for combination vaccines. Shingles vaccine tolerability data superior to competitors; Phase III pending partner feedback.
- **Financial Milestones**: $75M manufacturing tech transfer milestone in Q4 2026. 2026 supply sales driven by R21 malaria vaccine (25M doses distributed).

Novavax, Inc. (NVAX) Q3 2025 Earnings Call Transcript

- **$175M Milestone Achievement**: Received from Sanofi for U.S. Nuvaxovid approval, with additional $50M milestone expected in Q4 2025.
- **Partnership Expansion**: Takeda partnership optimized for Japan, R21 malaria vaccine sales exceed 20M doses.
- **R&D Progress**: CIC and flu vaccine show strong immune responses; H5N1 preclinical data supports single-dose efficacy.
- **Financial Restructuring**: 41% YoY expense reduction; 2025 revenue guidance raised to $1.0-1.05B.
- **2027 Profitability Target**: Non-GAAP breakeven achievable via Sanofi royalties and new partnerships.

**【CEO Summary Section】**
- Highlighted three strategic priorities: optimizing the Sanofi partnership, enhancing existing collaborations, and advancing the Matrix-M adjuvant platform.
- Received $175 million milestone from Sanofi for U.S. BLA approval of Nuvaxovid, with additional milestones expected in 2025-2026.
- Expanded partnership with Takeda for Japan, improving financial terms and operational efficiency.
- R21 Matrix-M malaria vaccine has sold over 20 million doses, addressing a critical public health need.
- Exploring new partnerships for Matrix-M adjuvant in oncology and other indications, with three MTAs signed.

**【CFO Financial Commentary】**
- Q2 2025 total revenue: $239 million (down 42% YoY), driven by $175 million Sanofi milestone and $27 million Takeda licensing revenue.
- Combined R&D and SG&A expenses reduced 41% YoY to $123 million, with SG&A down 57% due to commercial transition to Sanofi.
- Updated 2025 revenue framework: $1.0-1.05 billion, including $50 million from Sanofi milestones and $20 million from Takeda.
- Cash position: $850 million, targeting 1.5-2 years of runway; aiming for non-GAAP profitability by 2027.

**【Q&A Key Highlights】**
- **Post-Marketing Commitment (PMC) Study**: $70-90 million cost, 70% reimbursed by Sanofi; no impact on 2025-2026 operating profit.
- **CIC and Flu Vaccine**: Partner discussions ongoing; data shows strong immune responses vs. Fluzone high-dose, with T-cell responses a key differentiator.
- **Oncology Exploration**: Early data positive; leveraging Matrix-M adjuvant for potential cancer vaccines, with collaborations in early stages.
- **Sanofi Collaboration**: Sanofi comments highlight potential of COVID-flu combo vaccines, with both candidates under fast track.
- **H5N1 Vaccine**: Preclinical data shows single-dose efficacy, intranasal administration potential for reduced transmission.


Novavax, Inc. (NVAX) Q2 2025 Earnings Call Transcript

- **Strategic Shift Succeeding**: 2027 non-GAAP profitability target on track with 30% cost reduction.
- **Partnership Expansion**: Sanofi combo vaccines, Takeda Japan deal, and 4 new MTAs drive pipeline value.
- **Matrix-M Advantage**: Real-world data shows 39% fewer side effects vs. mRNA vaccines.
- **FDA Progress**: Constructive BLA discussions with potential approval pathway.

**【CEO Strategic Overview】**
- Transitioned from COVID-19 vaccine commercialization to a partnership-driven model, focusing on leveraging Matrix-M adjuvant technology.
- 2027 non-GAAP profitability target with 30% reduction in R&D/SG&A expenses by 2025.
- Key partnerships: Sanofi (COVID-flu combo vaccines), Takeda (Japan COVID market), and expanded MTAs with top pharma companies.

**【CFO Financial Highlights】**
- Q1 2025 revenue: $667M (vs. $94M YoY), driven by $603M from Canada/New Zealand APA terminations and $45M licensing/royalties.
- Cash balance: $798M, with $225M expected milestones from Sanofi and Takeda.
- Operating expenses: $137M (24% YoY decline), targeting $475-525M for 2025.

**【R&D Pipeline Updates】**
- Early-stage programs: H5N1, RSV combo, shingles, C. Difficile vaccines.
- Matrix-M adjuvant shows superior tolerability vs. mRNA vaccines (39% fewer symptoms in real-world study).
- Late-stage CIC/flu program Phase 3 data expected mid-2025, with intent to partner for pivotal trials.

**【Q&A Key Takeaways】**
- FDA BLA approval path: Constructive discussions, potential post-marketing commitment study.
- Takeda upfront payment: $20M Q2, enhancing Japan market access.
- CIC/flu vaccine safety: Matrix-M adjuvant expected to maintain favorable tolerability profile.
- 2025 revenue guidance raised to $975-1,025M, driven by APA terminations and supply sales growth.

Novavax, Inc. (NVAX) Q1 2025 Earnings Call Transcript

- **Strategic Milestones Achieved**: $200M gain from Czech facility sale, $80M annual cost savings, and $225M Sanofi milestones on track.
- **Pipeline Progress**: CIC vaccine Phase 3 data expected mid-2025; H5N1 vaccine shows single-dose efficacy in animals.
- **Financial Discipline**: 2025 R&D + SG&A target of $475-$525M, with $1B+ cash runway.
- **Partnership Potential**: Sanofi COVID-flu combo vaccines could generate $350M+ in milestones and royalties.
- **Innovation Focus**: Early-stage programs in C. Diff, RSV, and shingles leverage Matrix-M and AI for differentiation.


**【CEO Opening Remarks】**
- 2024 marked a transformative year for Novavax, with the launch of its COVID-19 vaccine and the partnership with Sanofi. The company achieved a $200 million gain from the sale of its Czech Republic manufacturing facility, reducing annual operating costs by $80 million.
- Key 2025 priorities include: (1) solidifying the Sanofi partnership to maximize royalties and milestones; (2) leveraging the Matrix-M adjuvant platform for new collaborations; (3) advancing early-stage pipeline programs in C. Diff, varicella-zoster, and RSV.

**【CFO Financial Overview】**
- 2024 total revenue: $682 million (product sales: $190 million; licensing/royalties: $492 million). Full-year R&D + SG&A expenses decreased 40% YoY to $700 million.
- 2025 guidance: R&D + SG&A expenses targeted at $475-$525 million, with a focus on cost reduction and strategic R&D investments. Cash position remains strong at over $1 billion post-Czech facility sale.

**【CFO 2025 Revenue Framework】**
- Adjusted licensing/royalties: $300-$350 million (includes $175M BLA approval milestone, $25M EU/US MAH transfer, and $15M pediatric database lock).
- Key external milestones: $225M from Sanofi (BLA approval and MAH transfer), with potential additional royalties from Sanofi's COVID-flu combo vaccines.

**【R&D Update】**
- **COVID-Flu Combo (CIC) Vaccine**: Phase 3 trial of 2,000 participants completed; topline data expected mid-2025. Novavax plans to partner post-data readout, with Sanofi leading commercialization.
- **Early-Stage Pipeline**: Four new programs (C. Diff, varicella-zoster, RSV combo, shingles) in preclinical stages. RSV combo leverages AI for antigen optimization and Matrix-M adjuvant for durability.
- **H5N1 Vaccine**: Preclinical data shows single-dose protection in non-human primates; seeking government funding for clinical trials.

**【Sanofi Partnership Update】**
- Sanofi assumes lead commercialization for COVID-19 vaccine in 2025, reducing Novavax's commercial costs. Sanofi initiated Phase 1/2 trials for COVID-flu combo vaccines (Fast Track designation), with potential $350M in milestones and royalties.
- Matrix-M adjuvant revenue potential: $200M per product in milestones and mid-single-digit royalties for 20 years.

**【Q&A Highlights】**
- **COVID-19 Vaccine Label**: FDA interactions positive; no pericarditis/myocarditis warnings anticipated. Strain change decision pending VRBPAC meeting.
- **CIC Vaccine Partnering**: Mid-2025 data will guide partnership strategy; focus on combo vaccine's immunogenicity and safety profile.
- **H5N1 Funding**: Novavax pursuing government grants; single-dose efficacy in animals supports pandemic preparedness potential.
- **RSV Program**: Differentiated approach with AI-optimized antigens and Matrix-M adjuvant; targeting durability and multivalent protection.


Actual												-0.58	-0.3	-3.21	-2.7	-3.05	-4.75	-4.31	-11.18	2.56	-6.53	-2.15	-2.28	-3.41	0.58	-1.26	-1.44	-1.05	0.99	-0.76	-0.51	2.93	0.62	-1.25	0.11
Forecast												-0.69	-0.506	1.7313	-2.2267	-3.598	-3.632	-3.907	-1.802	2.6883	3.6433	1.5683	-1.014	-3.462	-1.3317	-2.215	-0.448	-1.064	1.67	-0.7911	-0.514	-0.4233	0.0084	-1.1963	-0.4848
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+15.94%	+40.71%	-285.41%	-21.26%	+15.23%	-30.78%	-10.31%	-520.42%	-4.77%	-279.23%	-237.09%	-124.85%	+1.50%	+143.55%	+43.12%	-221.43%	+1.32%	-40.72%	+3.93%	+0.78%	+792.18%	+7280.95%	-4.49%	+122.69%

Actual	--	--	--	--	--	--	--	--	--	--	--	3.38M	35.54M	157.02M	279.66M	447.23M	298.02M	178.84M	222.20M	703.97M	185.93M	734.58M	357.40M	80.95M	424.43M	186.99M	291.34M	93.86M	415.48M	84.51M	88.31M	666.65M	239.24M	70.44M	147.14M
Forecast	--	--	--	--	--	--	--	--	--	--	--	1.93M	28.20M	230.56M	202.44M	233.90M	387.87M	334.53M	331.79M	845.20M	863.68M	586.25M	383.14M	87.61M	264.16M	115.42M	322.05M	101.16M	458.57M	73.78M	84.38M	343.85M	152.61M	42.13M	89.85M
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+74.83%	+26.02%	-31.89%	+38.15%	+91.21%	-23.17%	-46.54%	-33.03%	-16.71%	-78.47%	+25.30%	-6.72%	-7.60%	+60.67%	+62.00%	-9.54%	-7.22%	-9.40%	+14.54%	+4.66%	+93.88%	+56.77%	+67.21%	+63.77%

NVAX

NVAX fundamentals

NVAX Q4 2025 Earnings

Earnings Call

You can ask Aime

NVAX

NVAX fundamentals

NVAX Q4 2025 Earnings

Earnings Call

NVAX Earnings Call Summary for Q4/20258:30 AM on Feb 26, 2026

NVAX Earnings Call Summary for Q3/20258:30 AM on Nov 6, 2025

NVAX Earnings Call Summary for Q2/20258:30 AM on Aug 6, 2025

NVAX Earnings Call Summary for Q1/20258:30 AM on May 8, 2025

NVAX Earnings Call Summary for Q4/20248:30 AM on Feb 27, 2025

You can ask Aime